首页> 美国卫生研究院文献>The Oncologist >Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD) or Double Refractory to a PI and an IMiD
【2h】

Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD) or Double Refractory to a PI and an IMiD

机译:具有多于3种既往疗法且包括蛋白酶体抑制剂(PI)和免疫调节药物(IMiD)或对PI和IMiD双重耐药的多发性骨髓瘤患者的总生存率的真实数据分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background.This retrospective study evaluated the treatment patterns in and overall survival (OS) of multiple myeloma (MM) patients who were refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) or who had received three or more prior lines of therapy (LOTs) including a PI and an IMiD.
机译:背景:这项回顾性研究评估了多发性骨髓瘤(MM)患者的治疗方式和总生存期(OS),这些患者对蛋白酶体抑制剂(PI)和免疫调节药物(IMiD)无效,或者已经接受过3种或以上的抗肿瘤药物治疗治疗(LOT),包括PI和IMiD。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号